Pharma & Biotech

Neurocrine Biosciences is capturing significant attention from both the medical community and investors. The biotechnology firm is generating excitement with...

The investment narrative surrounding Crinetics Pharmaceuticals presents a complex puzzle for market participants. On one hand, institutional money is flowing...

Ultragenyx Pharmaceutical finds itself navigating turbulent market conditions, with its equity value experiencing a dramatic contraction of over fifty percent...

Pfizer finds itself navigating increasingly turbulent political waters as it works to reduce its reliance on COVID-related products. Simultaneous regulatory...

Nuvalent finds itself at a pivotal crossroads as the biotech company balances promising clinical developments against recent market uncertainties. Investors...

Investors in Agios Pharmaceuticals faced a sharp selloff after US regulators announced a three-month delay for the approval decision of...

While Aura Biosciences shares have been mired in a months-long downtrend, market analysts maintain strikingly optimistic price targets for the...

A significant safety notification from the U.S. Food and Drug Administration has disrupted Boston Scientific's positive trajectory. The regulatory warning...

Despite showcasing an aggressive expansion strategy through product launches and partnerships, Thermo Fisher Scientific is confronting a significant crisis of...

Pharmaceutical giant Bristol-Myers Squibb is undergoing a significant strategic transformation, marked by two major developments in key international markets this...